Literature DB >> 15851026

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.

Li Ma1, Zhenbang Chen, Hediye Erdjument-Bromage, Paul Tempst, Pier Paolo Pandolfi.   

Abstract

Tuberous sclerosis (TSC) is a tumor syndrome caused by mutation in TSC1 or TSC2 genes. TSC tumorigenesis is not always accompanied by loss of heterozygosity (LOH). Recently, extracellular signal-regulated kinase (Erk) has been found activated in TSC lesions lacking TSC1 or TSC2 LOH. Here, we show that Erk may play a critical role in TSC progression through posttranslational inactivation of TSC2. Erk-dependent phosphorylation leads to TSC1-TSC2 dissociation and markedly impairs TSC2 ability to inhibit mTOR signaling, cell proliferation, and oncogenic transformation. Importantly, expression of an Erk nonphosphorylatable TSC2 mutant in TSC2+/- tumor cells where Erk is constitutively activated blocks tumorigenecity in vivo, while wild-type TSC2 is ineffective. Our findings position the Ras/MAPK pathway upstream of the TSC complex and suggest that Erk may modulate mTOR signaling and contribute to disease progression through phosphorylation and inactivation of TSC2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15851026     DOI: 10.1016/j.cell.2005.02.031

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  542 in total

1.  Escherichia coli succinic thiolinase. Stoichiometry of phosphorylation and coenzyme A binding.

Authors:  C M Bowman; J S Nishimura
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

2.  Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice.

Authors:  Mahendra D Mavalli; Douglas J DiGirolamo; Yong Fan; Ryan C Riddle; Kenneth S Campbell; Thomas van Groen; Stuart J Frank; Mark A Sperling; Karyn A Esser; Marcas M Bamman; Thomas L Clemens
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

3.  MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis.

Authors:  M Su; J Wang; C Wang; X Wang; W Dong; W Qiu; Y Wang; X Zhao; Y Zou; L Song; L Zhang; R Hui
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

4.  mTOR Signaling and Entrainment of the Mammalian Circadian Clock.

Authors:  Ruifeng Cao; Karl Obrietan
Journal:  Mol Cell Pharmacol       Date:  2010

5.  Tetraspanin CD63 Bridges Autophagic and Endosomal Processes To Regulate Exosomal Secretion and Intracellular Signaling of Epstein-Barr Virus LMP1

Authors:  Stephanie N Hurwitz; Mujeeb R Cheerathodi; Dingani Nkosi; Sara B York; David G Meckes
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

Review 6.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

8.  The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Authors:  T R Hartman; E Nicolas; A Klein-Szanto; T Al-Saleem; T P Cash; M C Simon; E P Henske
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

9.  Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus.

Authors:  Yan Liu; Fan Liu; Hao Yu; Xinyang Zhao; Goro Sashida; Anthony Deblasio; Michael Harr; Qing-Bai She; Zhenbang Chen; Hui-Kuan Lin; Silvana Di Giandomenico; Shannon E Elf; Youyang Yang; Yasuhiko Miyata; Gang Huang; Silvia Menendez; Ingo K Mellinghoff; Neal Rosen; Pier Paolo Pandolfi; Cyrus V Hedvat; Stephen D Nimer
Journal:  Sci Signal       Date:  2012-10-23       Impact factor: 8.192

Review 10.  Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.

Authors:  Scott T Eblen
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.